


19 JUL 2004

Claims

REPLACED BY
ART 24 AMDT

1. Beta-secretase inhibitor of formula (I)



wherein


X: represents a halogen or a moiety which is bioisosteric thereto, in particular, F, Cl, Br, I, Methyl or CF₃, preferably Cl.

R₁: each independently represents halogen, hydroxy, cyano, trifluoromethyl, nitro, a hydrocarbon group containing 1 to 4 carbon atoms, in particular, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl, which may be substituted, e.g. hydroxyalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, acylalkyl, oxyalkyl, sulfonylalkyl, sulfonylamidoalkyl, amidoalkyl, carbonoylalkyl, ureylalkyl, etc. or a moiety which is bioisosteric thereto and n = 0 to 4, preferably n = 0 to 2.

R₂: is a connecting moiety from a group consisting of a single bond, or a C1-C8 hydrocarbon group such as a C1-C4 alkylene group, a C2-C8 alkenylene group, a C2-C8 alkynylene group, a C1-C4 alkylene group containing at least one heteroatom, a C2-C8 alkenylene group containing at least one heteroatom or a C2-C8 alkynylene group containing at least one heteroatom.

Cyc: is a carbocyclic, aryl or heterocyclic moiety.


R₃: each independently is a group being bound to the moiety Cyc and is selected from R₁ or is a aryl or heterocyclic moiety substituted by 0 to 4 moieties from R₁ or a group selected from



and $m = 0$ to 8 , in particular 0 to 4 .


- 5 2. Beta-secretase inhibitor according to claim 1 having the formula






10



15

20



REPLACED BY
ART 34 AMDT

3. Beta-secretase inhibitor according to claim 1 or 2,
having an $IC_{50} \leq 200 \mu M$.
4. Beta-secretase inhibitor according to any of claims 1 to 3,
being active in cells.
5. Beta-secretase inhibitor according to claim 1-4,
having a structure according to one of the formulas 1 to 118.
6. A pharmaceutical composition comprising a beta-secretase inhibitor
according to any of claims 1 to 5,
optionally in admixture with one or more pharmaceutically
acceptable carriers, diluents and/or excipients.
7. A substance library containing at least 5 beta-secretase inhibitors
according to any of claims 1 to 5.
8. The use of a beta-secretase inhibitor according to any of claims 1 to
5 for the manufacture of a pharmaceutical agent for the treatment or
prevention of a condition which is mediated by beta-secretase.
9. The use of a beta-secretase inhibitor according to any of claims 1 to
5 for the manufacture of a pharmaceutical agent to inhibit the
formation of beta amyloid peptides from the amyloid precursor
protein (APP).
10. The use according to claim 8 or 9 for the manufacture of a
pharmaceutical agent for the treatment or prevention of Alzheimer's
disease or any disorder caused by pathological deposits of beta
amyloid peptides.

11. Use of a beta-secretase inhibitor according to any of claims 1 to 5 in the manufacture of a pharmaceutical agent for the treatment or prevention of conditions selected from the group consisting of Alzheimer's disease, Down syndrome, cerebral amyloid angiopathy, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch type (HCHWA-D) and other degenerative dementia characterized by beta-amyloid deposits.
12. A method of treating or preventing a disease characterized by beta-amyloid deposits such as Alzheimer's disease by modulating the activity of the beta-amyloid converting enzyme, comprising administering to a patient in need of such treatment a compound according to claims 1 to 5, or a pharmaceutically acceptable salt thereof.